• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Elanco Animal Health Incorporated Common Stock (NY: ELAN )

    11.63 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Elanco Animal Health Incorporated Common Stock

    < Previous 1 2 3 4 5 6 Next >
    Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
    JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
    Via Benzinga
    This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
    Via Benzinga
    Top 3 Health Care Stocks That Could Blast Off In December
    Via Benzinga
    Analyst Ratings For Elanco Animal Health
    Via Benzinga
    Elanco Animal Health (ELAN) Q3 2024 Earnings Call Transcript
    ELAN earnings call for the period ending September 30, 2024. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Evaluating Elanco Animal Health: Insights From 4 Financial Analysts
    Via Benzinga
    Demystifying Elanco Animal Health: Insights From 4 Analyst Reviews
    Via Benzinga
    A Closer Look at 4 Analyst Recommendations For Elanco Animal Health
    Via Benzinga
    Elanco Animal Q3 Earnings: Profit Beat, New Products And Stabilized Business To Drive 2025 Sales
    Elanco Animal Health reports Q3 revenue of $1.03 billion, with a 4% decline and adjusted EPS of $0.13, beating estimates. Guidance tightened for 2024 sales and EPS. 
    Via Benzinga
    Elanco's Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy
    FDA approves Elanco's once-daily oral treatment, Zenrelia, for controlling itching in dogs with allergic and atopic dermatitis. The drug, proven effective in studies, faces adoption challenges due to... 
    Via Benzinga
    Exposures Product Safety
    Robinhood To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    The Latest Analyst Ratings For Elanco Animal Health
    Via Benzinga
    Breaking Down Elanco Animal Health: 6 Analysts Share Their Views
    Via Benzinga
    Elanco Animal Health (ELAN) Q2 2024 Earnings Call Transcript
    ELAN earnings call for the period ending June 30, 2024. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
    These are the healthcare stocks to buy as they represent companies with good fundamentals, stable growth visibility and cash flow upside. 
    Via InvestorPlace
    Merk Animal Health Completes Acquisition of Elanco Animal Health Assets
    Merck Animal Health announced the purchase of Elanco Animal Health's aquaculture business.Merck & Company (NYSE:MRK) completed the acquisition of the aquaculture bus 
    Via Benzinga
    Citigroup, Elanco Animal Health And A Tech Stock: CNBC's 'Final Trades'
    Analysts expect Citigroup to report good earnings on Friday. Stephanie Link chose Elanco for its new products. Corning increased its sales guidance. 
    Via Benzinga
    Elanco Animal Health Shares Sink On Unexpected Label Update For Canine Dermatology Drug
    Elanco Animal Health shares drop after updates on FDA approval timelines for Zenrelia and Credelio Quattro. Zenrelia's U.S. label includes a boxed warning, impacting adoption. U.S. launches for both... 
    Via Benzinga
    Exposures Product Safety
    Fluffy's Drugmaker Elanco Animal Health Plummets On Unexpected Safety Warning
    The company is working on treatments for eczema and parasite prevention. 
    Via Investor's Business Daily
    Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Bargain Bin: 3 Cheap Stocks to Buy Before Memorial Day
    Summer has arrived on Wall Street! Discover three cheap stocks to buy with solid fundamentals to boost your profitability this season. 
    Via InvestorPlace
    Elanco Animal Health's Q1 Earnings Show Improved Base Business, Analyst Highlights Slightly Delayed But Encouraging Pipeline
    Elanco Animal Health (NYSE: ELAN) reports Q1 results: adjusted EPS $0.34 (-26% Y/Y), sales $1.21B (-4% Y/Y). 2024 guidance: EPS $0.88-$0.96, revenue $4.46-$4.52 billion. 
    Via Benzinga
    Elanco Animal Health (ELAN) Q1 2024 Earnings Call Transcript
    ELAN earnings call for the period ending March 31, 2024. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    ELAN Stock Earnings: Elanco Animal Health Beats EPS, Beats Revenue for Q1 2024
    ELAN stock results show that Elanco Animal Health beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Elanco Makes A Bullish Move On Its First Quarter Beat; Are Pet Health Stocks Forging A Comeback?
    Elanco is the second animal health company to report better-than-expected first-quarter metrics. 
    Via Investor's Business Daily
    Investor Activism: Elanco Animal Health Settles with Ancora, Adds New Board Members
    Elanco Animal Health settles with Ancora, expanding board to 14 members, including Ancora's nominees Craig Wallace and Kathy Turner. Ancora's significant stake in Elanco, approximately $250 million,... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.